CA
NBIX icon

Crewe Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Crewe Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2
Closed -$252 – 1029
2025
Q2 		$252 Hold
2
– – ﹤0.01% 717
2025
Q1 		$222 Hold
2
– – ﹤0.01% 691
2024
Q4 		$273 Buy
+2
New +$247 ﹤0.01% 620
2024
Q2 		– Sell
-700
Closed -$96.5K – 1006
2024
Q1 		$96.5K Buy
+700
New +$95.6K 0.01% 279
2023
Q2 		– Sell
-124
Closed -$12.6K – 970
2023
Q1 		$12.6K Hold
124
– – ﹤0.01% 504
2022
Q4 		$14.8K Hold
124
– – ﹤0.01% 473
2022
Q3 		$13K Hold
124
– – ﹤0.01% 585
2022
Q2 		$12K Buy
+124
New +$11.4K ﹤0.01% 554
2020
Q4 		– Sell
-6
Closed -$1K – 581
2020
Q3 		$1K Buy
+6
New +$694 ﹤0.01% 595

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Crewe Advisors's NBIX Position: Q3 2025 in Review

Crewe Advisors sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 2 shares — an estimated $252 sold.

Crewe Advisors first reported a position in NBIX in Q3 2020 and held it in 9 quarters. The position peaked at $96.5K in Q1 2024. 650 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Crewe Advisors reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Crewe Advisors sold 2 Neurocrine Biosciences shares in Q3 2025, an estimated $252.
  • Crewe Advisors first reported a position in Neurocrine Biosciences in Q3 2020 and held it in 9 quarters.
  • Crewe Advisors's Neurocrine Biosciences position peaked at $96.5K in Q1 2024.
  • 650 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Crewe Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.